@article{c2eca4f1348a4d0e9fa0e9d5af8f543c,
title = "Intravenous Thrombolysis before Endovascular Thrombectomy for Acute Ischemic Stroke",
author = "Saver, \{Jeffrey L.\} and Opeolu Adeoye",
note = "Funding Information: Diagnostics Inc, which is developing a brain monitoring device for which the University of Cincinnati holds the patent. The University of Cincinnati receives grant support from the NIH for Dr Adeoye{\textquoteright}s leadership role in the Multi-arm Optimization of Stroke Thrombolysis (MOST) trial and the Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN). Dr Adeoye reported receiving hourly payments and travel reimbursement for services as a scientific consultant advising on clinical trial design and conduct to Genentech. Funding Information: stroke. The University of California received payments on the basis of clinical trial contracts for the number of participants enrolled in multicenter clinical trials sponsored by Medtronic, Stryker, Cerenovus, BrainsGate, NONO Inc, and Boehringer Ingelheim (prevention only). The University of California receives grant support from the National Institutes of Health (NIH) for Dr Saver{\textquoteright}s service in leadership roles in the National Institute of Neurological Disorders and Stroke StrokeNet national clinical trial network and from Diffusion Pharma for Dr Saver{\textquoteright}s leadership role in the PHAST-TSC multicenter trial. Dr Saver reported serving as an unpaid consultant to Genentech advising on the design and conduct of the PRISMS trial; neither the University of California nor Dr Saver received any payments for this voluntary service. Dr Saver paid for his own travel. Dr Saver reported receiving contracted hourly payments and travel reimbursement for services as a scientific consultant advising on rigorous trial design and conduct to Medtronic, Stryker, Cerenovus, BrainsGate, Boehringer Ingelheim (prevention only), NONO Inc, BrainQ, and Abbott; contracted stock options for services as a scientific consultant advising on rigorous trial design and conduct to Rapid Medical; and personal fees from Johnson \& Johnson and Novo Nordisk. Dr Adeoye reported being an employee of the University of Cincinnati. He is cofounder and equity holder for Sense",
year = "2021",
month = jan,
day = "19",
doi = "10.1001/jama.2020.22388",
language = "English",
volume = "325",
pages = "229--231",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
number = "3",
}